FOLH1 and urothelial carcinoma: INO-5401, a DNA vaccine targeting Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (PSMA), and hTERT, is evaluated in two phase I/IIa studies, in combination with atezolizumab in a urothelial carcinoma study (NCT03502785) and in combination with cemiplimab (anti-PD-L1) in newly diagnosed glioblastoma (NCT03491683), respectively.